Site icon pharmaceutical daily

Traveler’s Diarrhea – Global Market Insights, Epidemiology and Forecast to 2028 – ResearchAndMarkets.com

BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Traveler’s
Diarrhea – Market Insights, Epidemiology and Market Forecast – 2028”
drug pipelines has been added to ResearchAndMarkets.com’s
offering.

This report delivers an in-depth understanding of the disease,
historical & forecasted epidemiology as well as the market trends of
Traveler’s Diarrhea (TD) in the United States, EU5 (Germany, Spain,
Italy, France and United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs,
market share of the individual therapies, and current and forecasted
market size of Traveler’s Diarrhea (CCA) from 2017 to 2028 segmented by
seven major markets.

The report also covers current treatment practice/algorithm, market
drivers, market barriers and unmet medical needs to curate best of the
opportunities and assess underlying potential of the market.

Geography Covered

Study Period: 2017-2028

Traveler’s Diarrhea (TD) Epidemiology

The Traveler’s Diarrhea (TD) epidemiology division provide the insights
about historical and current patient pool and forecasted trend for every
7 major countries. The epidemiology data for Traveler’s Diarrhea (TD)
are studied through all possible division to give a better understanding
about the Disease scenario in 7MM. It also helps to recognize the causes
of current and forecasted trends by exploring numerous studies, survey
reports and views of key opinion leaders.

Traveler’s Diarrhea (TD) Epidemiology Segmentation

The disease epidemiology covered in the report is segmented by total
incident population, diagnosed population and severity-specific incident
population of Traveler’s Diarrhea.

The report also provides the epidemiology trends observed in the 7MM
during the study period, along with the assumptions undertaken. The
calculated data are presented with relevant tables and graphs to give a
clear view of the epidemiology at first sight.

According to the publisher, the incident population of Traveler’s
Diarrhea (TD) was estimated to be 41,611,405 [7MM] in 2018. United
States accounts for the highest TD cases (16,964,730 in 2018), followed
by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5
countries Germany had the highest incident patient population of
Traveler’s Diarrhea, followed by Italy.

Traveler’s Diarrhea (TD) Drug Chapters

This segment of the Traveler’s Diarrhea (TD) report encloses the
detailed analysis of marketed drugs and late stage (Phase-III) pipeline
drugs. It also helps to understand the clinical trial details,
expressive pharmacological action, agreements and collaborations,
approval and patent details, advantages and disadvantages of each
included drug and the latest news and press releases.

The treatment therapies comprise of oral hydration and diet modification
strategy followed by Anti-motility drugs or antidiarrheal drugs (also
known as symptomatic therapy) and Antibiotics/Antimicrobials. The first
step is Oral Hydration that involves replenishment of fluids and
electrolytes with the first goal of prevention and treatment of
dehydration. The symptomatic relief is provided by Anti-motility agents.
The most common treatments include bismuth subsalicylate and Synthetic
opiates such as loperamide and diphenoxylate that can reduce frequency
of bowel movements and therefore enable travelers to ride on an airplane
or bus.

The symptomatic treatment is followed by antimicrobial strategies
including antibiotics. Antibiotic therapy is recommended either with or
without loperamide for travelers with moderate to severe symptoms (three
or more unformed stools during an 8-h period, particularly if associated
with nausea, vomiting, abdominal cramping, fever, or bloody stools).
Marketed drugs for traveler’s diarrhea include Aemcolo (rifamycin, Cosmo
Pharmaceuticals), Xifaxan (rifaximin, Salix Pharmaceuticals). Detailed
chapters for all of these drugs, as well as another promising candidates
have been covered in the report.

Traveler’s Diarrhea (TD) Market Outlook

The Traveler’s Diarrhea (TD) market outlook of the report helps to build
the detailed comprehension of the historic, current and forecasted trend
of the market by analyzing the impact of current therapies on the
market, unmet needs, drivers and barriers and demand of better
technology.

This segment gives a through detail of market trend of each marketed
drug and late-stage pipeline therapy by evaluating their impact based on
annual cost of therapy, inclusion and exclusion criteria’s, mechanism of
action, compliance rate, growing need of the market, increasing patient
pool, covered patient segment, expected launch year, competition with
other therapies, brand value, their impact on the market and view of the
key opinion leaders. The calculated market data are presented with
relevant tables and graphs to give a clear view of the market at first
sight.

According to the publisher, the global market of Traveler’s Diarrhea
(TD) was estimated to be USD 385.07 million in 2018. The United States
accounts for the largest market size of Traveler’s Diarrhea, in
comparison to EU5 (the United Kingdom, Germany, Italy, France, and
Spain), and Japan. Currently, includes surgery with adjuvant
chemotherapy and chemoradiation therapy. For the advanced and metastatic
stage, systemic chemotherapy is the only option. There is no established
second-line systemic therapy following progression after first-line
treatment although chemotherapeutic agents either in monotherapy or in
combination are used.

To meet the increasing demand for the treatment of Traveler’s Diarrhea
(TD), companies have shifted their focus towards the development of
targeted therapies. Expected launch of potential targeted therapies
including potential FGFR gene fusions and somatic mutations in IDH 1/2
in iCCA, PRKACA or PRKACB gene fusions in pCCA, and ELF3 mutations in
dCCA/ampullary carcinoma, may increase the market size in the coming
years, assisted by an increase in the incident population of Traveler’s
Diarrhea (TD) & awareness of the disease.

Traveler’s Diarrhea (TD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs
recently launched in the market or will get launched in the market
during the study period from 2017-2028. The analysis covers market
uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake,
reasons behind the maximal use of new drugs and allows the comparison of
the drugs on the basis of market share and size which again will be
useful in investigating factors important in market uptake and in making
financial and regulatory decisions.

The dynamics of Traveler’s Diarrhea market is anticipated to change in
the coming years owing to the expected launch of emerging therapies
during the forecasted period 2019-2028. Key players are working robustly
on new therapies with novel mechanism of action, including Ivosidenib
(Agios Pharmaceuticals), Pemigatinib (Incyte Corporation), Infigratinib
(QED Therapeutics), Melphalan Hydrochloride (Delcath Systems),
Regorafenib (Bayer), Larotrectinib (Loxo Oncology), Entrectinib
(Hoffmann-La Roche), Derazantinib (Basilea Pharmaceutica) and
Erdafitinib(Janssen Research & Development).

Traveler’s Diarrhea (TD) Report Insights

Traveler’s Diarrhea (TD) Report Key Strengths

Traveler’s Diarrhea (TD) Report Assessment

Key Benefits

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/9roj0n

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Gastrointestinal
Drugs

Exit mobile version